Prothena AI Stock Analysis
Want to see PRTA full AI Analyst Report?
Prothena (PRTA) AI Stock Analysis
Prothena
(NASDAQ:PRTA)
The score is held down primarily by weak financial performance (ongoing losses and deteriorating negative free cash flow) and bearish technicals (price below key moving averages with negative MACD). Valuation is difficult to assess due to negative earnings and no dividend yield data, while a recent negative corporate event (PRX019 license termination) adds incremental program and funding-risk pressure despite continued potential from the moponetug partnership.
Prothena Key Performance Indicators (KPIs)
Revenue by SegmentShows how much revenue each business segment generates, highlighting which parts of the company are driving growth and which may need strategic adjustments.
Revenue is clearly episodic—driven by partner milestone and license payments rather than recurring product sales—so pronounced spikes represent one‑off partner payments tied to clinical progress. Management highlighted meaningful near‑term upside (up to $105M in 2026 and larger multi‑billion potential milestones) but excludes these from base guidance, so cash runway and valuation hinge on milestone timing and partner decisions. Model Prothena as event‑driven: focus on upcoming partner catalysts and cash burn, not steady organic revenue growth.
Prothena (PRTA) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $419.01M
- Dividend Yield
- ―
- Average Volume (3M)
- 466.33K
- Price to Earnings (P/E)
- -17.4
- Beta (1Y)
- 0.92
- Revenue Growth
- 347.44%
- EPS Growth
- 91.00%
- Country
- US
- Employees
- 67
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Prothena Business Overview & Revenue Model
Company Description
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized...
How the Company Makes Money
Prothena primarily generates revenue through collaboration and license arrangements rather than product sales, as it is a clinical-stage company. Under these agreements, Prothena can earn (1) upfront payments when a partnership is initiated or when a...
Prothena Earnings Call Summary
The call conveyed meaningful scientific and business progress — two partner programs advanced to Phase III, strong Phase II biomarker signals (40% reduction in a PD motor endpoint subset; 48% NT‑proBNP reduction for coramitug), introduction of a novel CYTOPE technology with encouraging preclinical TDP‑43 results, and a solid year‑end cash position ($308.4M). Material near‑term upside exists (up to $105M in 2026 milestones and ~ $3B in potential future milestones across partners). Offsetting risks include ARIA‑E safety concerns for PRX012 prompting re‑engineering, some non‑statistically significant secondary endpoints (6‑minute walk test), multi‑year timelines to Phase III primary completions (2029), continued net losses and burn, and reliance on partner decisions for key programs (PRX019). Overall, positives — pipeline advancement, strong partner validation, and a healthy cash balance — outweigh the operational and timing risks.
Q4-2025 Updates
Positive Updates
Negative Updates
Company Guidance
Prothena's 2026 guidance calls for full‑year net cash used in operating and investing activities of $50–55 million, an estimated net loss of $67–72 million (which includes about $24 million of noncash share‑based compensation), and an expected year‑end cash, cash equivalents and restricted cash balance of approximately $255 million at the midpoint; this guidance does not include up to $105 million of potential aggregate clinical milestone payments from partners in 2026. For context, Prothena closed 2025 with $308.4 million in cash (as of Dec 31, 2025), reported 2025 net cash used in operating and investing activities of $163.7 million (favorable to prior guidance of $170–178 million), a 2025 net loss of $244.1 million (in line with guidance of $240–248 million), had 53.8 million ordinary shares outstanding as of Feb 12, 2026, and a simple capital structure with zero debt.
Prothena Financial Statement Overview
Summary
Overall fundamentals are pressured by multi-year operating losses and persistent negative free cash flow (TTM OCF about -$31.4M; TTM FCF about -$32.2M, worsening ~47% vs prior period). The balance sheet is a relative strength with very low leverage (TTM debt-to-equity ~0.02), but the equity base has shrunk materially and ROE is negative, underscoring ongoing burn and dilution risk. Revenue remains volatile and recently contracted (TTM down ~3.3%), consistent with a higher-risk, milestone-driven biotech profile.
Income Statement
24NegativeBalance Sheet
68PositiveCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 52.73M | 9.68M | 135.16M | 91.37M | 53.91M | 200.58M |
| Gross Profit | 50.88M | 5.98M | 135.16M | 91.37M | 53.91M | 200.58M |
| EBITDA | -23.35M | -199.93M | -128.04M | -159.55M | -124.86M | 73.04M |
| Net Income | -23.96M | -244.09M | -122.31M | -147.03M | -116.95M | 66.97M |
Balance Sheet | ||||||
| Total Assets | 283.52M | 326.80M | 547.11M | 696.38M | 758.03M | 609.37M |
| Cash, Cash Equivalents and Short-Term Investments | 271.37M | 307.53M | 471.39M | 618.83M | 710.41M | 579.09M |
| Total Debt | 6.26M | 13.86M | 10.84M | 11.84M | 6.47M | 12.33M |
| Total Liabilities | 14.68M | 46.33M | 60.18M | 135.02M | 135.99M | 143.32M |
| Stockholders Equity | 268.84M | 280.47M | 486.93M | 561.37M | 622.04M | 466.04M |
Cash Flow | ||||||
| Free Cash Flow | -32.17M | -163.72M | -150.35M | -136.72M | -109.28M | 92.03M |
| Operating Cash Flow | -31.45M | -163.58M | -150.05M | -133.91M | -108.82M | 92.61M |
| Investing Cash Flow | -725.00K | -138.00K | -298.00K | -2.77M | -464.00K | -575.00K |
| Financing Cash Flow | -27.30M | -139.00K | 1.55M | 45.10M | 241.46M | 190.33M |
Prothena Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRTA, the sentiment is Negative. The current price of 8.16 is below the 20-day moving average (MA) of 8.42, below the 50-day MA of 8.54, and below the 200-day MA of 9.17, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 45.77 is Neutral, neither overbought nor oversold. The STOCH value of 53.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRTA.
Prothena Risk Analysis
Prothena disclosed 62 risk factors in its most recent earnings report. Prothena reported the most risks in the "Tech & Innovation" category.
Latest Risks Added
0 New RisksProthena Peers Comparison
Overall Rating
ALEC58Neutral
AVXL46Neutral
PRTA46Neutral
ACIU45Neutral
IKT40Underperform
ABOS38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 58Neutral | $378.15M | 7.26 | 112.21% | ― | 151.23% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | $86.53M | -6.35 | -11.43% | ― | ― | 73.28% | |
| 46Neutral | $419.01M | -17.36 | -8.34% | ― | 347.44% | 91.00% | |
| 45Neutral | $216.78M | -4.46 | -104.05% | ― | 384.77% | 38.30% | |
| 40Underperform | $213.21M | -3.41 | -40.53% | ― | ― | 28.48% | |
| 38Underperform | $15.48M | -0.14 | -166.49% | ― | ― | 29.92% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PRTA | Prothena Corporation | 8.16 | -2.09 | -20.39% | |
| AVXL | Anavex Life Sciences | 0.93 | -2.65 | -73.94% | |
| ACIU | AC Immune | 2.13 | -0.97 | -31.29% | |
| ALEC | Alector | 2.54 | 1.30 | 104.84% | |
| IKT | Inhibikase Therapeutics, Inc. | 1.52 | 0.00 | 0.00% | |
| ABOS | Acumen Pharmaceuticals, Inc. | 0.21 | -1.37 | -86.46% |
Prothena Corporate Events
Prothena Faces PRX019 License Termination by Bristol Myers
NegativeOn October 28, 2026, Bristol Myers Squibb notified Prothena that it would not advance PRX019 further in clinical development, leading to the termination of their exclusive global license agreement for the candidate effective January 28, 2027. PRX019...
Prothena Chief Development Officer Resigns for Partner Role
NeutralOn October 2, 2026, Prothena announced that its Chief Development Officer, Chad J. Swanson, Ph.D., has resigned effective October 9, 2026, to take a role with one of the company’s strategic partners. In his new position, Dr. Swanson will assume a lea...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 06, 2026
